Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory of Molecular Epidemiology of Birth Defects, |
RCV003154782 | SCV003843706 | likely pathogenic | Ovarian cancer | 2022-01-01 | criteria provided, single submitter | clinical testing | |
KCCC/NGS Laboratory, |
RCV004813223 | SCV005437118 | likely pathogenic | Exostoses, multiple, type 2 | 2024-12-16 | criteria provided, single submitter | clinical testing | a likely pathogenic variant in the EXT2 gene (heterozygous, Gln424Lys). This sequence alteration replaces glutamine, a neutral and polar amino acid, with lysine at codon 424 of the MSH2 protein (p.Gln424Lys). This amino acid position is highly conserved, with a PhyloP score of 7.71.ClinVar includes an entry for this variant (Variation ID: 2445372), which has been classified as likely pathogenic based on a single submission from West China Second University in the context of ovarian cancer. In silico predictions from SIFT and PolyPhen indicate that this variant is likely deleterious.Consequently, we classify this variant as likely pathogenic. The heterozygous mutation in EXT2 is typically associated with multiple exostoses, type 2 (OMIM #133701), which is an autosomal dominant skeletal disorder characterized by the development of multiple benign bone growths (osteochondromas) on the long bones of the limbs. |